UGT1A10: A Drug Target / Disease Biomarker (G54575)

Target Name: UGT1A10

NCBI ID: G54575

UGT1A10

UGT1A10: A Drug Target / Disease Biomarker

UGT1A10 is a gene that has been identified as a potential drug target or biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its function is related to the detoxification of xenobiotics, which are harmful substances that can be found in many foods, as well as in environmental and industrial waste.

The UGT1A10 gene is a member of the UGT family of enzymes, which are responsible for breaking down a wide variety of compounds, including drugs, toxins, and other harmful substances. The UGT1A10 gene is specifically involved in the detoxification of thiopurine drugs, which are commonly used to treat autoimmune disorders and some types of cancer.

Thiopurine drugs work by blocking the action of a protein called Pgp, which is involved in the detoxification of many different types of compounds. In order to work effectively, Pgp needs to be expressed in the cells of the body, but it can also be expressed in the cells of cancer cells, which can make these drugs ineffective.

The UGT1A10 gene helps to regulate the expression of Pgp, which is critical for the effectiveness of thiopurine drugs. When UGT1A10 is expressed in the cells of the body, it helps to reduce the amount of Pgp that is expressed, which can make the drugs more effective.

In addition to its role in the detoxification of thiopurine drugs, UGT1A10 may also be involved in the detoxification of other types of compounds that are harmful to the body. For example, it has been shown to be involved in the detoxification of arsenic, which is a toxic compound that can be found in natural and industrial environments.

The UGT1A10 gene is also thought to be involved in the development and progression of certain neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells, which can lead to a range of symptoms, including cognitive decline and difficulty with daily activities.

Recent studies have suggested that UGT1A10 may also be involved in the development of certain types of cancer, including breast and ovarian cancer. These cancers are characterized by the growth of abnormal cells in the body, which can lead to a range of symptoms and a decreased quality of life.

In addition to its potential clinical applications, the UGT1A10 gene is also of interest to researchers because of its role in the detoxification of a wide variety of compounds. This makes it a potential target for new drugs or biomarkers that can be used to diagnose and treat a range of diseases.

Overall, the UGT1A10 gene is a promising target for new drugs or biomarkers that can be used to treat a variety of diseases. Further research is needed to fully understand its function and potential clinical applications.

Protein Name: UDP Glucuronosyltransferase Family 1 Member A10

Functions: UDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite's water solubility, thereby facilitating excretion into either the urine or bile (PubMed:12181437, PubMed:18004212, PubMed:18052087, PubMed:18674515, PubMed:18719240, PubMed:19545173, PubMed:23288867, PubMed:26220143). Essential for the elimination and detoxification of drugs, xenobiotics and endogenous compounds (PubMed:12181437, PubMed:18004212). Catalyzes the glucuronidation of endogenous estrogen hormones such as estradiol, estrone and estriol (PubMed:18719240, PubMed:23288867, PubMed:26220143). Also catalyzes the glucuronidation of the isoflavones genistein, daidzein, glycitein, formononetin, biochanin A and prunetin, which are phytoestrogens with anticancer and cardiovascular properties (PubMed:18052087, PubMed:19545173). Involved in the glucuronidation of the AGTR1 angiotensin receptor antagonist losartan, caderastan and zolarsatan, drugs which can inhibit the effect of angiotensin II (PubMed:18674515)

The "UGT1A10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UGT1A10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets